论文部分内容阅读
目的:探讨阿德福韦酯治疗活动性代偿期乙肝肝硬化的临床应用及疗效。方法:选取于我院实施治疗的活动性代偿期乙肝肝硬化患者71例,按就诊顺序随机分为观察组(31例)与对照组(30例),分别给予常规治疗+阿德福韦酯、常规治疗,对比两组临床疗效。结果:观察组的治疗有效率明显高于对照组(96.8%vs76.7%),不良反应发生率明显低于对照组(6.5%vs16.7%),且肝功能指标的改善水平明显优于对照组,P<0.05,有统计学意义。结论:阿德福韦酯治疗活动性代偿期乙肝肝硬化,可有效改善患者的肝功能,缓解临床症状,不良反应少、疗效确切,值得推广。
Objective: To investigate the clinical application and curative effect of adefovir dipivoxil in active decompensated hepatitis B cirrhosis. Methods: Seventy one patients with decompensated hepatitis B cirrhosis who were treated in our hospital were randomly divided into observation group (n = 31) and control group (n = 30) according to the order of treatment, and were given routine treatment plus adefovir Ester, conventional treatment, compared the clinical efficacy of two groups. Results: The treatment efficiency in the observation group was significantly higher than that in the control group (96.8% vs76.7%), the incidence of adverse reactions was significantly lower than that in the control group (6.5% vs16.7%), and the improvement of liver function was significantly better than Control group, P <0.05, with statistical significance. Conclusion: Adefovir dipivoxil treatment of active compensated hepatitis B cirrhosis can effectively improve the patient’s liver function, relieve clinical symptoms, fewer adverse reactions, the curative effect is worthy of promotion.